Omnipod 5 Delivers Superior Economic Value Compared to Multiple Daily Injections: A Cost‐Effectiveness Analysis in Adults With T1D From a Payer Perspective in Sweden
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71231 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Johan Jendle und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Sciences, Örebro University, Örebro, Sweden. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin, Insulin Infusion Systems. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Insulet Corporation.
Abstract (Originalsprache)
Aim
Analyse the cost‐effectiveness of the Omnipod 5 automated insulin delivery system versus multiple daily injections (MDI) with continuous glucose monitoring for type 1 diabetes among adults in Sweden.
Methods
Cost‐effectiveness was analysed with the IQVIA Core Diabetes Model (version 10.0) taking the perspective of the payer in Sweden including healthcare system and combined healthcare system and societal costs. Treatment effects were derived from the RADIANT randomised controlled trial and acute complication rates from Biester et al. 2021. Treatment‐specific health utilities were sourced from a Time Trade‐Off (TTO) elicitation study. Incremental costs, life expectancy, quality‐adjusted life‐years (QALY) and incremental cost–utility ratios (ICURs) were calculated using a 50‐year time horizon for the base case and sensitivity analysis tested changes in parameters including treatment effects, baseline HbA1c and time horizons.
Results
Omnipod 5 was found to be cost‐effective in the base case and sensitivity analyses, with ICURs below the willingness‐to‐pay threshold of 500 000 SEK per QALY. In the base case Omnipod 5 was found to have lower rates of diabetes‐related complications and provide 3.82 in additional QALY. Higher therapy costs with Omnipod 5 were offset by savings in the cost of complications and savings in costs associated with absenteeism. Considering direct costs only the ICUR was 201 161 SEK per QALY. Considering combined costs it was 179 247 SEK per QALY.
Conclusion
Omnipod 5 was found to offer superior value compared with MDI, showing cost‐effectiveness for adults with type 1 diabetes in Sweden with better patient outcomes and fewer complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Sciences, Örebro University, Örebro, Sweden.
- Insulet, London, UK.
- IQVIA, Gurgaon, India.
- Nordic Infucare AB, Bromma, Sweden.
ORCID-Profile: Raffaele Scarica
Förderung
- Insulet Corporation
Zitieren
APA
Jendle, J., Hopley, C., Narang, A., Scarica, R., Hellerstedt, H., & Littlewood, M. (2026). Omnipod 5 Delivers Superior Economic Value Compared to Multiple Daily Injections: A Cost‐Effectiveness Analysis in Adults With T1D From a Payer Perspective in Sweden. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71231
Vancouver
Jendle J, Hopley C, Narang A, Scarica R, Hellerstedt H, Littlewood M. Omnipod 5 Delivers Superior Economic Value Compared to Multiple Daily Injections: A Cost‐Effectiveness Analysis in Adults With T1D From a Payer Perspective in Sweden. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71231
BibTeX
@article{Jendle2026,
author = {Jendle, Johan and Hopley, Colin and Narang, Anuj and Scarica, Raffaele and Hellerstedt, Helena and Littlewood, Melanie},
title = {Omnipod 5 Delivers Superior Economic Value Compared to Multiple Daily Injections: A Cost‐Effectiveness Analysis in Adults With T1D From a Payer Perspective in Sweden},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71231}
}
EUVIMED